Trial Profile

A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 May 2025 According to an Endeavor BioMedicines Media Release, new clinical findings from a post-hoc analysis from the completed Phase 2a clinical trial were presented in a poster presentation at the American Thoracic Society (ATS) 2025 International Conference.
22 May 2024 Results presented at the 120th International Conference of the American Thoracic Society
19 May 2024 According to an Endeavor BioMedicines Media Release, company recently announced the closing of a $132.5 million Series C financing that will support clinical development of ENV-101 in IPF and PPF.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com